Researchers at The University of Texas MD Anderson Cancer Center have developed a bioinformatics platform that predicts optimal treatment combinations for a given group of patients based on co-occurring tumor alterations. In retrospective validation studies, the tool selected combinations that resulted in improved patient outcomes across both pre-clinical and clinical studies.
Combining a retrospective analysis of clinical records with in-depth laboratory studies, researchers at The University of Texas MD Anderson Cancer Center have discovered that vitamin E can enhance immunotherapy responses by stimulating the activity of dendritic cells in the tumor.
Susana Garcia-Recio, a research associate in the lab of Charles M. Perou at the UNC Lineberger Comprehensive Cancer Center, presented findings at the 2022 AACR annual meeting that identified molecular features responsible for the development and progression of metastatic breast cancer.
Following an analysis of over 12,000 human genes, research from Yale Cancer Center indicated there is cancer-relevant importance in a much larger proportion of human genes than current cancer research models suggest.
Data generated using the Duomic platform, sponsored by IsoPlexis Corporation, demonstrated the ability to connect T-cell receptor diversity to the most functionally potent single cells, according to findings presented at the 2022 AACR annual meeting.
African-American adult patients are more likely than white patients to receive substandard gastrointestinal cancer surgery, according to a large study led by researchers at Yale Cancer Center.
Using the nation’s largest COVID-19 data resource, a researcher at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center found the COVID-19 vaccine protected most cancer patients from getting COVID-19. However, patients with certain types of cancer have a higher and widely varied risk of breakthrough infections after receiving the vaccine.
A retrospective, observational study sponsored by G1 Therapeutics described the burden of myelosuppression and its impact on healthcare resource utilization in 3,277 patients being treated with chemotherapy for extensive-stage small-cell lung cancer. The study also described patient outcomes from 21 patients receiving Cosela (trilaciclib) prior to chemotherapy.
Researchers from VCU Massey Cancer Center, the University of Florida College of Medicine, and UF Health Cancer Center found that minority patient participation in cancer clinical trials is low—in part due to standard clinical trial criteria that disproportionately exclude Black patients.
Researchers at Fox Chase Cancer Center who looked at over 34,000 colorectal cancer patients found that certain PTEN mutations occur in distinct patterns in specific subsets of colorectal cancer.
